Despite considerable efforts to prevent and treat cardiovascular disease (CVD), it has become the leading cause of death worldwide. Cardiac mitochondria are crucial cell organelles responsible for creating energy-rich ATP and mitochondrial dysfunction is the root cause for developing heart failure. Therefore, maintenance of mitochondrial quality control (MQC) is an essential process for cardiovascular homeostasis and cardiac health. In this review, we describe the major mechanisms of MQC system, such as mitochondrial unfolded protein response and mitophagy. Moreover, we describe the results of MQC failure in cardiac mitochondria. Furthermore, we discuss the prospects of 2 drug candidates, urolithin A and spermidine, for restoring mitochondrial homeostasis to treat CVD.

Despite considerable efforts to prevent and treat cardiovascular disease (CVD), it has become the leading cause of death worldwide. Cardiac mitochondria are crucial cell organelles responsible for creating energy-rich ATP and mitochondrial dysfunction is the root cause for developing heart failure. Therefore, maintenance of mitochondrial quality control (MQC) is an essential process for cardiovascular homeostasis and cardiac health. In this review, we describe the major mechanisms of MQC system, such as mitochondrial unfolded protein response and mitophagy. Moreover, we describe the results of MQC failure in cardiac mitochondria. Furthermore, we discuss the prospects of 2 drug candidates, urolithin A and spermidine, for restoring mitochondrial homeostasis to treat CVD.
Adenosine Triphosphate ; Cardiovascular Diseases ; Cause of Death ; Heart Failure ; Heart ; Homeostasis ; Mitochondria ; Mitochondrial Degradation ; Organelles ; Quality Control ; Spermidine ; Unfolded Protein Response

The Korean Society for Thoracic and Cardiovascular Surgery (KTCVS) was founded in 1968 and celebrated the 50th anniversary of its founding in 2018. The launch of the KTCVS may seem somewhat recent, given that the American Association for Thoracic Surgery was founded in 1917. However, considering the circumstances of the Korean medical community after the Japanese occupation (1910–1945), World War II (1940–1945), and the Korean War (1950–1953), this apparent delay is understandable. Even before the foundation of the KTCVS, the early pioneers of thoracic and cardiovascular surgery promptly adopted medical technologies from more advanced countries such as the United States, and contributed significantly to both cardiac and thoracic surgery despite difficult circumstances. In 2012, before the 50th anniversary of the founding of the KTCVS, members shared the opinion that objective records of the activities of the early pioneers should be identified and preserved, and reacted positively towards the necessity for historians who would preserve such records. With this background, the Historical Records Preservation Committee of the KTCVS (hereinafter, referred to as ‘the Committee’) was launched. The Committee published a white paper on the history of thoracic and cardiovascular surgery in 2015 and held an exhibition of the achievements of the pioneers at the 50th anniversary of the founding of the KTCVS. The Committee also published a book entitled “The history of Korean thoracic surgery with photographs: celebrating the 50th anniversary of the society.” The Committee will keep making efforts to find and preserve materials related to activities during the early development of thoracic and cardiovascular surgery in Korea.
Anniversaries and Special Events ; Asian Continental Ancestry Group ; Humans ; Korea ; Korean War ; Occupations ; Thoracic Surgery ; United States ; World War II

No abstract available.
Korea ; Thoracic Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (KTCVS) was founded in 1968 and celebrated the 50th anniversary of its founding in 2018. The launch of the KTCVS may seem somewhat recent, given that the American Association for Thoracic Surgery was founded in 1917. However, considering the circumstances of the Korean medical community after the Japanese occupation (1910–1945), World War II (1940–1945), and the Korean War (1950–1953), this apparent delay is understandable. Even before the foundation of the KTCVS, the early pioneers of thoracic and cardiovascular surgery promptly adopted medical technologies from more advanced countries such as the United States, and contributed significantly to both cardiac and thoracic surgery despite difficult circumstances. In 2012, before the 50th anniversary of the founding of the KTCVS, members shared the opinion that objective records of the activities of the early pioneers should be identified and preserved, and reacted positively towards the necessity for historians who would preserve such records. With this background, the Historical Records Preservation Committee of the KTCVS (hereinafter, referred to as ‘the Committee’) was launched. The Committee published a white paper on the history of thoracic and cardiovascular surgery in 2015 and held an exhibition of the achievements of the pioneers at the 50th anniversary of the founding of the KTCVS. The Committee also published a book entitled “The history of Korean thoracic surgery with photographs: celebrating the 50th anniversary of the society.” The Committee will keep making efforts to find and preserve materials related to activities during the early development of thoracic and cardiovascular surgery in Korea.

PURPOSE: The number of laparoscopy assisted distal gastrectomies (LADG) is gradually increasing for the treatment of early gastric cancer (EGC) patients as a surgical modality for improving quality of life. However, there are few reports on laparoscopy-assisted total gastrectomy (LATG), mainly because this procedure is performed relatively infrequently, and the procedure is more complicated than LADG. This study was performed to evaluate the technical feasibility, safety, and surgical results of LATG with lymphadenectomy through a review of our experience. MATERIALS AND METHODS: From July 2003 to June 2007, 77 LATG with Roux-en-Y esophagojejunostomy were performed for patients with a preoperative diagnosis of EGC. The clinicopathological features and surgical outcomes were analyzed. RESULTS: There were 49 males and 28 females in the study with a mean age of 61 years (range 30~85 years). The mean operation time was 210 minutes (range 100~400 minutes) and the operation time was gradually decreased as the case numbers increased. There were 13 operative morbidities (16.9%) and no operative mortalities. The restoration of bowel motility was noted at 3.2 postoperative days; a soft diet was started at 4.4 postoperative days and the duration of hospital stay was 10 days. There were 20 mucosal lesions, 32 submucosal lesions, 15 proper muscle lesions, 7 subserosal lesions and 3 serosal lesions. A total of 20 patients were treated by D2 lymph node dissection, 55 patients were treated by D1+beta lymph node dissection, and two patients were treated by D1 + alpha lymph node dissection. The mean number of retrieved lymph nodes was 42 (range 11~86). Lymph node metastases were noted in 12 patients CONCLUSION: This study indicated LATG could be applied safely and effectively for patients with EGC. However, a prospective study comparing laparoscopy-assisted versus open gastrectomy for short-term and long-term surgical outcome is needed.
Diagnosis ; Diet ; Female ; Gastrectomy* ; Humans ; Laparoscopy* ; Length of Stay ; Lymph Node Excision* ; Lymph Nodes* ; Male ; Mortality ; Neoplasm Metastasis ; Quality of Life ; Stomach Neoplasms

OBJECTIVE: New nonsteroidal anti-inflammatory drugs (NSAIDs) with highly selective cyclooxygenase-2 (COX-2) inhibition afford protection against gastropathy, but their acute and long-term effects on the central nervous system are unclear. Our aim was to investigate the influence of COX-2 specific inhibitor (celecoxib) on cognitive function. METHODS: Within the context of a randomized controlled parallel trial of NSAIDs for osteoarthitis (OA), we performed a battery of neuropsychological tests in consecutive 10 osteoarthritis patients with celecoxib (200 mg/day) and 13 osteoarthritis patients with diclofenac (100 mg/day) before and after 4 weeks by clinical psychologists who were not involoved in the study and unaware of study protocols and treatment allocation. The tests were performed randomly in sequence in order to minimize learning effect. The examed cognitive domains included memory, reasoning/problem solving, simple and complex attention, visual-spatial processing, and psychomotor speed. RESULTS: Demographic characteristcs (age, sex, disease duration, functional status measured by patient's and physician's global assessment and KWOMAC, CES depression score, education level) were not significantly different between both treatment groups. In all cognitive domains, we did not find out significant cognitive decline before and after treatments either with celecoxib or diclofenac. There was no difference in the change of cognitive function between both treatment groups. CONCLUSION: The short-term use of COX-2 specific inhibitor as well as conventional NSAID may not impair cognitive function. The long-term follow up study using large number of patients is in progress.
Anti-Inflammatory Agents, Non-Steroidal ; Central Nervous System ; Cognition ; Cyclooxygenase 2 ; Depression ; Diclofenac ; Education ; Follow-Up Studies ; Humans ; Learning ; Memory ; Neuropsychological Tests ; Osteoarthritis ; Pilot Projects* ; Psychology ; Celecoxib

OBJECTIVE: To assess the health-related quality of life (HRQOL), the correlation among each measurement, and to identify the predictors for HRQOL in Korean patients with ankylosing spondylitis (AS). METHODS: The HRQOL and clinical and laboratory parameters were assessed by Short Form Health Survey-36 (SF-36), EuroQol5 Dimensions (EQ-5D), time trade off (TTO), standard gamble (SG), Centers for Epidemiologic StudiesDepression (CES-D), social support, self-efficacy scale, Bath Ankylosing Spondylitis Functional Index (BASFI), Schober test, occiput to wall test, ESR, and CRP from 90 patients with AS. RESULTS: 78 patients (86.7%) were men with a mean (+/-SD) age of 28.4 (+/-7.9) years. The mean years of disease onset was 10.44 (+/-6.95). The mean scores of SF-36 global, mental component summary (MCS) and physical component summary (PCS) were 53.4 (+/-21.2), 61.8 (+/-26.3), and 51.7 (+/-24.4), respectively. The mean EQ-5D utility and visual analog scale (VAS) score were 0.63 (+/-0.2) and 57.1 (+/-18.6). The mean scores of the TTO and SG were 0.46 (+/-0.6) and 0.46 (+/-0.6). The scores of the SF-36 and EQ-5D in AS patients were lower than those in healthy control. The mean scores of CES-D, self-efficacy scale, social support and social network were 10.5 (+/-6.8), 65.3 (+/-14.6), 2.46 (+/-0.22), and 2.33 (+/-0.47), respectively. The mean score of BASFI was 2.48 (+/-2.13). The BASFI total score was negatively correlated with the scores of SF-36, MCS, PCS, EQ-5D utility and VAS score, social network, and self-efficacy scale, and positively correlated with CES-D. In multivariate models, the predicting variables of SF-36 global and PCS were BASFI and self-efficacy scale and the predicting variables of SF-36 MCS were BASFI, social support, and self-efficacy scale. CONCLUSION: In this study, we observed that HRQOL in Korean patients with ankylosing spondylitis is decreased compare to healthy control. And the efforts to improve HRQOL should be designed to improve the self-efficacy and social support in addition to active treatment to prevent functional disability.
Baths ; Humans ; Male ; Quality of Life* ; Spondylitis, Ankylosing* ; Visual Analog Scale

BACKGROUND AND OBJECTIVES: Recent studies have shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure (HF)-associated hospitalization and mortality in patients with diabetes. However, it is not clear whether SGLT2 inhibitors have a cardiovascular benefit in patients without diabetes. We aimed to determine whether empagliflozin (EMPA), an SGLT2 inhibitor, has a protective role in HF without diabetes. METHODS: Cardiomyopathy was induced in C57BL/6J mice using intraperitoneal injection of doxorubicin (Dox). Mice with HF were fed a normal chow diet (NCD) or an NCD containing 0.03% EMPA. Then we analyzed their phenotypes and performed in vitro experiments to reveal underlying mechanisms of the EMPA's effects. RESULTS: Mice fed NCD with EMPA showed improved heart function and reduced fibrosis. In vitro studies showed similar results. Phloridzin, a non-specific SGLT inhibitor, did not show any protective effect against Dox toxicity in H9C2 cells. SGLT2 inhibitor can cause increase in blood ketone levels. Beta hydroxybutyrate (βOHB), which is well known ketone body associated with SGLT2 inhibitor, showed a protective effect against Dox in H9C2 cells and in Dox-treated mice. These results suggest elevating βOHB might be a convincing mechanism for the protective effects of SGLT2 inhibitor. CONCLUSIONS: SGLT2 inhibitors have a protective effect in Dox-induced HF in mice. This implied that SGLT2 inhibitor therapy could be a good treatment strategy even in HF patients without diabetes.
3-Hydroxybutyric Acid ; Animals ; Cardiomyopathies ; Diet ; Doxorubicin ; Doxycycline ; Fibrosis ; Heart Failure ; Heart ; Hospitalization ; Humans ; In Vitro Techniques ; Injections, Intraperitoneal ; Mice ; Mortality ; Phenotype ; Phlorhizin